Filtered By:
Specialty: Hematology
Condition: Hemorrhagic Stroke
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 295 results found since Jan 2013.
Direct Oral Anticoagulants in Patients with Myeloproliferative Neoplasms: A Single Institution Retrospective Study
Discussion: Our limited data suggests that use of DOACs in patients with MPN is feasible with an acceptable balance between risk of hemorrhage and recurrent thrombosis. Additional data on long term outcomes of DOACs in MPNs are needed.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Deloughery, E. P., McBane, R. D., Ashrani, A. A., Tefferi, A., Slusser, J. P., Pruthi, R. K. Tags: 332. Antithrombotic Therapy Source Type: research
Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients
In conclusion, most patients had achieved the target INR at the time of ICH, and the primary precipitant of fatal ICH was often a fall. Using DOACs instead of warfarin and implementing structured fall-prevention programs in high-risk patients could further reduce mortality from ICH in AF.
Source: Journal of Thrombosis and Thrombolysis - November 17, 2018 Category: Hematology Source Type: research
Modified DWI-FLAIR mismatch guided thrombolysis in unknown onset stroke
AbstractDWI-FLAIR mismatch has been recently proven to identify patients with unknown onset stroke (UOS) eligible for thrombolysis. However, this concept may exclude patients from thrombolysis who may eventually benefit as well. We aimed to examine the feasibility, safety and potential efficacy of thrombolysis in wake-up stroke (WUS) and UOS patients using a modified DWI-FLAIR mismatch allowing for partial FLAIR positivity. WUS/UOS patients fulfilling the modified DWI-FLAIR mismatch and treated with intravenous thrombolysis (IVT) were compared to propensity score matched WUS/UOS patients excluded from IVT due to FLAIR posi...
Source: Journal of Thrombosis and Thrombolysis - November 10, 2018 Category: Hematology Source Type: research
Management of dabigatran after overdosage: two case reports and suggestions for monitoring
We describe two different cases with very high overdosage in which PCC or idarucizumab was used to reverse the effect of dabigatran etexilate.
Source: Blood Coagulation and Fibrinolysis - October 17, 2018 Category: Hematology Tags: CASE REPORTS Source Type: research
Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel
AbstractThis randomized double-blind crossover study aimed to investigate the influence of cytochrome P450 (CYP) 2C19 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke treated with clopidogrel. Patients received clopidogrel 75 mg/day for> 4 weeks. Subsequently, patients received prasugrel 3.75 mg/day (group A;n = 64) or 2.5 mg/day (group B;n = 65) for 4 weeks followed by a 4 week switched-dose regimen. To assess the influence of CYP2C19 polymorphisms, patients were classified as extensive metabolizers (EMs), intermediate metabolizers (IMs), and poor metabo...
Source: Journal of Thrombosis and Thrombolysis - October 5, 2018 Category: Hematology Source Type: research
Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials
AbstractTenecteplase is a genetically mutated variant of alteplase with superior pharmacodynamic and pharmacokinetic properties. However, its efficacy and safety in acute ischemic strokes are limited. Hence, we conducted a study to evaluate the efficacy and safety of tenecteplase compared with alteplase in acute ischemic stroke. Electronic databases were searched for randomized clinical trials (RCTs) comparing tenecteplase with alteplase in acute ischemic stroke patients eligible for thrombolysis. We evaluated various efficacy and safety outcomes using random-effects models for both pairwise and Bayesian network meta-analy...
Source: Journal of Thrombosis and Thrombolysis - October 5, 2018 Category: Hematology Source Type: research
The efficacy and safety of Batroxobin in combination with anticoagulation on cerebral venous sinus thrombosis
This study aims to evaluate the safety and efficacy of Batroxobin in combination with anticoagulation on CVST control. In this retrospective study, a total of 61 CVST patients were enrolled and divided into Batroxobin (n = 23) and control (n = 38) groups. In addition to the same standard anticoagulation in control, patients in the treatment group received Batroxobin 5 BU intravenous infusion (10 BU for the first time) every other day, for a total of three infusions. A higher recanalization rate was found in Batroxobin group (adjusted OR [95% CI] of 2.5 [1.1–5.0],p = 0.028) compared to the control group, es...
Source: Journal of Thrombosis and Thrombolysis - September 10, 2018 Category: Hematology Source Type: research
Preadmission use of Glucocorticoids and Risk of Cardiovascular Events in Patients with Ischemic Stroke.
CONCLUSIONS: During the first year after ischemic stroke, current glucocorticoid use was associated with moderately increased risk of myocardial infarction and venous thromboembolism and lower risk of hemorrhagic stroke, while the risk of recurrent ischemic stroke was not affected. This article is protected by copyright. All rights reserved.
PMID: 30179297 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 4, 2018 Category: Hematology Authors: Sundbøll J, Darvalics B, Horváth-Puhó E, Adelborg K, Laugesen K, Schmidt M, Henderson VW, Sørensen HT Tags: J Thromb Haemost Source Type: research
Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials
AbstractTenecteplase is a genetically mutated variant of alteplase with superior pharmacodynamic and pharmacokinetic properties. However, its efficacy and safety in acute ischemic strokes are limited. Hence, we conducted a study to evaluate the efficacy and safety of tenecteplase compared with alteplase in acute ischemic stroke. Electronic databases were searched for randomized clinical trials (RCTs) comparing tenecteplase with alteplase in acute ischemic stroke patients eligible for thrombolysis. We evaluated various efficacy and safety outcomes using random-effects models for both pairwise and Bayesian network meta-analy...
Source: Journal of Thrombosis and Thrombolysis - August 16, 2018 Category: Hematology Source Type: research
Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel
AbstractThis randomized double-blind crossover study aimed to investigate the influence of cytochrome P450 (CYP) 2C19 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke treated with clopidogrel. Patients received clopidogrel 75 mg/day for> 4 weeks. Subsequently, patients received prasugrel 3.75 mg/day (group A;n = 64) or 2.5 mg/day (group B;n = 65) for 4 weeks followed by a 4 week switched-dose regimen. To assess the influence of CYP2C19 polymorphisms, patients were classified as extensive metabolizers (EMs), intermediate metabolizers (IMs), and poor metabo...
Source: Journal of Thrombosis and Thrombolysis - August 3, 2018 Category: Hematology Source Type: research
Appropriateness of non-vitamin K antagonist oral anticoagulant dose in patients with atrial fibrillation in Israel: A population-based study
The non-vitamin K oral antagonists (NOACs) are at least as effective as warfarin in the prevention of stroke in non valvular atrial fibrillation (NVAF) and are associated with less intracranial hemorrhage. Many patients with NVAF inappropriately do not receive anticoagulants often because of the inconvenience associated with warfarin administration. NOACs have the potential to increase anticoagulation use because they are safer and easier to administer than warfarin. Indeed, the use of anticoagulation in patients with newly diagnosed AF in many countries is increasing as a result of the use of NOACs in preference to warfarin [1].
Source: Thrombosis Research - July 24, 2018 Category: Hematology Authors: Martin H. Ellis, Sari Greenberg Dotan, Ariel Hammerman, Erez Battat, Estela Derazne, Orly Avnery Tags: Letter to the Editors-in-Chief Source Type: research
No Association between Thrombin Generation and Intra-Plaque Haemorrhage in Symptomatic Carotid Atherosclerotic Plaques: The Plaque at RISK (PARISK) Study.
CONCLUSION: Features of carotid plaque on MRI show no significant association with TG in stroke patients. Systemic TG does not seem to be an important factor in IPH development.
PMID: 29972860 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 4, 2018 Category: Hematology Authors: Crombag GAJC, Spronk HM, Nelemans P, Schreuder FHBM, Truijman MTB, van Dijk AC, de Rotte AAJ, Liem MI, Daemen MJAP, van der Steen AFW, Mess WH, Nederkoorn PJ, Hendrikse J, van der Lugt A, Wildberger JE, Ten Cate H, van Oostenbrugge RJ, Kooi ME Tags: Thromb Haemost Source Type: research
Hemostasis in the Very Young
Semin Thromb Hemost DOI: 10.1055/s-0038-1660852Hemostasis is a dynamic process that starts in utero. The coagulation system evolves with age, as evidenced by marked physiological differences in the concentration of the majority of hemostatic proteins in early life compared with adulthood. This concept, known as “developmental hemostasis,” has important biological and clinical implications. Overall, impaired platelet function, along with physiologically reduced levels of vitamin K–dependent and contact coagulation factors, may cause poorer clot firmness even in healthy neonates. However, increased activity of von Will...
Source: Seminars in Thrombosis and Hemostasis - June 18, 2018 Category: Hematology Authors: Kenet, Gili Barg, Assaf Arie Nowak-G öttl, Ulrike Tags: Review Article Source Type: research
Can an anticoagulant reduce brain hemorrhage: Invited comment on “Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization”
During studies of anti-coagulants to prevent cardioembolic stroke, startling data emerged that patients treated with novel oral anti-coagulants (NOACs) appeared to suffer less brain hemorrhage than patients treated with traditional, vitamin-K depleting anticoagulants [1, 2]. That NOACs reduced the bleeding risk did not fit accepted dogma: clinicians imagine that hemorrhage occurs during and following ischemic stroke as the brain undergoes necrosis. In the presence of anti-coagulation, such necrotic bleeding ought to be augmented.
Source: Thrombosis Research - June 11, 2018 Category: Hematology Authors: Patrick D. Lyden Tags: Editorial Source Type: research
Causes of Death in Patients with Venous Thromboembolism Anticoagulated with Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis
Semin Thromb Hemost DOI: 10.1055/s-0038-1642644Death is more frequent than nonfatal recurrent venous thromboembolism (VTE) and major bleeding after acute VTE. The analysis of the causes of death is fundamental to explore new strategies to reduce mortality rates in these patients. The authors performed a meta-analysis to analyze mortality and independently adjudicated causes of death in anticoagulated patients due to VTE, and to evaluate potential differences between different anticoagulant schemes. They searched MEDLINE and CENTRAL, from January 1, 2000, to January 31, 2017, and performed additional searches in Web sites o...
Source: Seminars in Thrombosis and Hemostasis - May 3, 2018 Category: Hematology Authors: G ómez-Outes, Antonio Terleira-Fern ández, Ana Isabel Lecumberri, Ram ón Su árez-Gea, Mª Luisa Calvo-Rojas, Gonzalo Vargas-Castrill ón, Emilio Tags: Review Article Source Type: research
